Chronic Lymphocytic Leukemia

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

Paolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

A survey of adult patients with chronic lymphocytic leukemia demonstrated that respondents preferred therapies that increased PFS vs other attributes.

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

Acalabrutinib and zanubrutinib monotherapy displayed better real-world safety and efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma compared with ibrutinib.

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs chemoimmunotherapy and vs venetoclax plus rituximab in frontline CLL.

David L. Porter, MD, discusses the utility of CAR T-cell therapy in the community setting for relapsed/refractory chronic lymphocytic leukemia.

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

David L. Porter, MD, discusses the future of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

Kathleen A. Dorritie, MD, discusses the significance of results from the phase 3 NCRI-FLAIR study in previously untreated chronic lymphocytic leukemia.

David L. Porter, MD, discusses knowledge gaps regarding the optimal use of CAR T-cell therapy in relapsed/refractory chronic lymphocytic leukemia.

Jean L. Koff, MD, MS, discusses the safety profile of pirtobrutinib in pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.

David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.